Enteropathy-Associated T-Cell Lymphoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ENT008 MIFTS: 39	Enteropathy-Associated T-Cell Lymphoma Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Enteropathy-Associated T-Cell Lymphoma

MalaCards integrated aliases for Enteropathy-Associated T-Cell Lymphoma:

Name: Enteropathy-Associated T-Cell Lymphoma ⁵⁴ ⁶⁰ ⁷⁴

High-Grade Pleomorphic Peripheral T-Cell Lymphoma ⁵⁴

Enteropathy-Type T-Cell Lymphoma ⁶⁰

Intestinal T-Cell Lymphoma ⁶⁰

Eatcl ⁵⁴

Eatl ⁶⁰

Ettl ⁶⁰

Characteristics:

Orphanet epidemiological data:

⁶⁰

enteropathy-associated t-cell lymphoma
Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴ ³⁵

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Other specified types of T/NK-cell lymphoma

Enteropathy-type (intestinal) T-cell lymphoma

Orphanet: ⁶⁰

Rare gastroenterological diseases

Rare haematological diseases

External Ids:

ICD10 ³⁴ C86.2

MESH via Orphanet ⁴⁶ D058527

ICD10 via Orphanet ³⁵ C86.2

UMLS via Orphanet ⁷⁵ C0456889

Orphanet ⁶⁰ ORPHA86880

UMLS ⁷⁴ C0456889

Sources

Summaries for Enteropathy-Associated T-Cell Lymphoma

MalaCards based summary : Enteropathy-Associated T-Cell Lymphoma, also known as high-grade pleomorphic peripheral t-cell lymphoma, is related to lymphoma and celiac disease 1. An important gene associated with Enteropathy-Associated T-Cell Lymphoma is SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase), and among its related pathways/superpathways are Akt Signaling and G-protein signaling_Regulation of RAC1 activity. The drugs Xalkori and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include t cells, small intestine and testes, and related phenotypes are hematopoietic system and immune system

Wikipedia : ⁷⁷ Enteropathy-associated T-cell lymphoma (EATL), previously termed enteropathy-associated T-cell lymphoma,... more...

Sources

Related Diseases for Enteropathy-Associated T-Cell Lymphoma

Diseases related to Enteropathy-Associated T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 38)

#	Related Disease	Score	Top Affiliating Genes
1	lymphoma	11.1
2	celiac disease 1	10.7
3	refractory celiac disease	10.5
4	diarrhea	10.2
5	histiocytosis	10.2
6	malignant histiocytosis	10.2
7	autoimmune enteropathy	10.2
8	polymorphic reticulosis	10.2
9	marginal zone b-cell lymphoma	10.1
10	cauda equina syndrome	10.1
11	composite lymphoma	10.1
12	anemia, autoimmune hemolytic	10.1
13	myocardial infarction	10.1
14	cholangitis, primary sclerosing	10.1
15	hemolytic anemia	10.1
16	hemophagocytic lymphohistiocytosis	10.1
17	peripheral t-cell lymphoma	10.1
18	ulcerative colitis	10.1
19	colitis	10.1
20	jejunoileitis	10.1
21	obstructive jaundice	10.1
22	sclerosing cholangitis	10.1
23	intestinal perforation	10.1
24	restrictive cardiomyopathy	10.1
25	reticulosarcoma	10.1
26	cholangitis	10.1
27	hypereosinophilic syndrome	10.1
28	lymphoma, hodgkin, classic	10.1
29	lymphoma, non-hodgkin, familial	10.1
30	spondylocarpotarsal synostosis syndrome	10.1
31	hepatosplenic t-cell lymphoma	10.1
32	immunodysregulation, polyendocrinopathy, and enteropathy, x-linked	9.9
33	anaplastic large cell lymphoma	9.9
34	common variable immunodeficiency	9.9
35	erythema multiforme	9.9
36	lymphangioma	9.9
37	cavernous lymphangioma	9.9
38	proteasome-associated autoinflammatory syndrome 1	9.6	CCL11 SETD2

Graphical network of the top 20 diseases related to Enteropathy-Associated T-Cell Lymphoma:

Sources

Symptoms & Phenotypes for Enteropathy-Associated T-Cell Lymphoma

MGI Mouse Phenotypes related to Enteropathy-Associated T-Cell Lymphoma:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	9.26	CCL11 CD3G ITGAE SETD2
2	immune system	MP:0005387	8.92	CCL11 CD3G ITGAE SETD2

Sources

Drugs & Therapeutics for Enteropathy-Associated T-Cell Lymphoma

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁹	Company	Approval Date
1	Xalkori ¹⁹ ⁵⁰	CRIZOTINIB	Pfizer	August of 2011
FDA Label: Xalkori Disease/s that Drug Treats:ALK+ non-small cell lung cancer Indications and Usage: ¹⁹ XALKORI is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplasticlymphoma kinase (ALK)-positive as detected by an FDA-approved test. (1), XALKORI is a kinase inhibitor indicated for the treatment of patients with: * metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (1.1) * metastatic NSCLC whose tumors are ROS1-positive. (1.2) DrugBank Targets: ¹⁶ 1. ALK tyrosine kinase receptor;2. Hepatocyte growth factor receptor, ALK tyrosine kinase receptor\|Hepatocyte growth factor receptor Mechanism of Action: ¹⁹ Target: receptor tyrosine kinases, receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur dâOrigine Nantais (RON) Action: inhibitor FDA: Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor(HGFR, c-Met), ROS1 (c-ros), and Recepteur dâOrigine Nantais (RON). Translocations can affect the ALKgene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results inactivation and dysregulation of the geneâs expression and signaling which can contribute to increased cellproliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependentinhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines anddemonstrated antitumor activity in mice bearing tumor xenografts that expressed EML4- or NPM-ALK fusionproteins or c-Met. , Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur dâOrigine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in activation and dysregulation of the geneâs expression and signaling which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines and demonstrated antitumor activity in mice bearing tumor xenografts that expressed echinoderm microtubule-associated protein-like 4 (EML4)- or nucleophosmin (NPM)-ALK fusion proteins or c-Met.

Drugs for Enteropathy-Associated T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Prednisone

Approved, Vet_approved

Phase 4,Phase 1,Phase 2,Early Phase 1

53-03-2

5865

Ifosfamide

Approved

Phase 4,Phase 2,Phase 1,Early Phase 1

3778-73-2

3690

Etoposide

Approved

Phase 4,Phase 2,Phase 1,Early Phase 1

33419-42-0

36462

Vincristine

Approved, Investigational

Phase 4,Phase 2,Phase 1

2068-78-2, 57-22-7

5978

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4,Early Phase 1

50-02-2

5743

Epirubicin

Approved

Phase 4,Phase 2

56420-45-2

41867

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 2,Phase 1,Early Phase 1

50-18-0, 6055-19-2

2907

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4,Early Phase 1

1177-87-3

Cisplatin

Approved

Phase 4,Phase 2

15663-27-1

2767 441203 84093

Gemcitabine

Approved

Phase 4,Phase 2

95058-81-4

60750

leucovorin

Approved

Phase 4,Phase 2,Early Phase 1

58-05-9

143 6006

Methotrexate

Approved

Phase 4,Phase 2,Early Phase 1

1959-05-2, 59-05-2

126941

Doxorubicin

Approved, Investigational

Phase 4,Phase 2,Phase 1,Early Phase 1

23214-92-8

31703

Mechlorethamine

Approved, Investigational

Phase 4,Phase 1,Early Phase 1

51-75-2

4033

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 2,Early Phase 1

59-30-3

6037

Doxil

Approved June 1999

Phase 4,Phase 2,Phase 1,Early Phase 1

31703

Pirarubicin

Investigational

Phase 4

72496-41-4

Hormones

Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable

Anti-Bacterial Agents

Phase 4,Phase 2,Phase 1,Early Phase 1

Antimitotic Agents

Phase 4,Phase 2,Phase 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 2,Phase 1,Early Phase 1

Alkylating Agents

Phase 4,Phase 2,Phase 1,Early Phase 1

Topoisomerase Inhibitors

Phase 4,Phase 2,Phase 1,Early Phase 1

Antineoplastic Agents, Hormonal

Phase 4,Phase 2,Phase 1,Early Phase 1

Immunosuppressive Agents

Phase 4,Phase 2,Phase 1,Early Phase 1

Antirheumatic Agents

Phase 4,Phase 2,Phase 1,Early Phase 1

Anti-Inflammatory Agents

Phase 4,Phase 2,Phase 1,Early Phase 1

glucocorticoids

Phase 4,Phase 2,Phase 1,Early Phase 1

Etoposide phosphate

Phase 4,Phase 2,Phase 1,Early Phase 1

Immunologic Factors

Phase 4,Phase 2,Phase 1,Early Phase 1

Antibiotics, Antitubercular

Phase 4,Phase 2,Phase 1,Early Phase 1

BB 1101

Phase 4,Early Phase 1

Antineoplastic Agents, Phytogenic

Phase 4,Phase 2,Phase 1,Early Phase 1

Hormone Antagonists

Phase 4,Phase 2,Phase 1,Early Phase 1

Isophosphamide mustard

Phase 4,Phase 2,Phase 1,Early Phase 1

Antineoplastic Agents, Alkylating

Phase 4,Phase 2,Phase 1,Early Phase 1

Vitamin B Complex

Phase 4,Phase 2,Early Phase 1

Folate

Phase 4,Phase 2,Early Phase 1

Dermatologic Agents

Phase 4,Phase 2,Phase 1,Early Phase 1

Vitamin B9

Phase 4,Phase 2,Early Phase 1

Antimetabolites, Antineoplastic

Phase 4,Phase 2,Phase 1,Early Phase 1

Antimetabolites

Phase 4,Phase 2,Phase 1,Early Phase 1

Nucleic Acid Synthesis Inhibitors

Phase 4,Phase 2,Early Phase 1

Folic Acid Antagonists

Phase 4,Phase 2,Early Phase 1

Methylprednisolone

Approved, Vet_approved

Phase 2

83-43-2

6741

Cytarabine

Approved, Experimental, Investigational

Phase 2

147-94-4, 65-46-3

6253

Carmustine

Approved, Investigational

Phase 2

154-93-8

2578

Methylprednisolone hemisuccinate

Approved

Phase 2

2921-57-5

Melphalan

Approved

Phase 2

148-82-3

460612 4053

Prednisolone phosphate

Approved, Vet_approved

Phase 2

302-25-0

Interventional clinical trials:

(show all 22)

#	Name	Status	NCT ID	Phase	Drugs
1	CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL	Unknown status	NCT02533700	Phase 4	CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2	CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma	Active, not recruiting	NCT01746992	Phase 4	Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3	High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma	Unknown status	NCT00669812	Phase 2	carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
4	CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma	Unknown status	NCT02742727	Phase 1, Phase 2
5	Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma	Completed	NCT00901147	Phase 2	panobinostat and bortezomib
6	SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma	Completed	NCT00787527	Phase 1, Phase 2	Zolinza (vorinostat);Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
7	CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.	Recruiting	NCT03217643	Phase 2	Brentuximab Vedotin
8	Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma	Recruiting	NCT03075553	Phase 2
9	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma	Recruiting	NCT03113500	Phase 2	Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Etoposide;Prednisone
10	A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)	Recruiting	NCT02588651	Phase 2	Brentuximab vedotin
11	CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study	Active, not recruiting	NCT01719835	Phase 2	Cyclophosphamide;Gemcitabine;Doxorubicin;Vincristine;Prednisolone;methylprednisolone;Cisplatin
12	Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma	Active, not recruiting	NCT02561273	Phase 1, Phase 2	Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
13	Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma	Terminated	NCT00810576	Phase 2	Vorinostat;Bortezomib
14	Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma	Completed	NCT01590732	Phase 1	Carboplatin;Etoposide;Ifosfamide;Romidepsin
15	Study of MLN8237 in Participants With Advanced Hematological Malignancies	Completed	NCT00697346	Phase 1	Alisertib
16	T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas	Recruiting	NCT03049449	Phase 1	Cyclophosphamide;Fludarabine
17	Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma	Terminated	NCT00671112	Phase 1	Bortezomib;Everolimus
18	Comparison Between Axial- and Lateral-viewing Capsule Endoscopy in Celiac Disease	Unknown status	NCT03095573	Not Applicable
19	Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma	Recruiting	NCT03719105	Early Phase 1	Methotrexate;pralatraxate,;Ifosfamide;Dexamethasone;Etoposide;Pegaspargase;cyclophosphamide;Doxorubicin;Prednisone;Brentuximab Vedotin
20	Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency	Recruiting	NCT01787409	Not Applicable
21	MAgnetic Resonance Imaging in COeliac Disease	Active, not recruiting	NCT02551289
22	Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma	Active, not recruiting	NCT02652715	Not Applicable

Search NIH Clinical Center for Enteropathy-Associated T-Cell Lymphoma

Sources

Genetic Tests for Enteropathy-Associated T-Cell Lymphoma

Sources

Anatomical Context for Enteropathy-Associated T-Cell Lymphoma

MalaCards organs/tissues related to Enteropathy-Associated T-Cell Lymphoma:

⁴²

T Cells, Small Intestine, Testes, B Cells, Bone, Colon, Lymph Node

Sources

Publications for Enteropathy-Associated T-Cell Lymphoma

Articles related to Enteropathy-Associated T-Cell Lymphoma:

(show top 50) (show all 137)

#	Title	Authors	Year
1	Hypocalcemia Revealing an Enteropathy-Associated T-cell Lymphoma. ( 30858951 )	Alonso Ortiz MB...Gonzalez IP	2019
2	Intestinal T-cell lymphoma with enteropathy-associated T-cell lymphoma-like features arising in the setting of adult autoimmune enteropathy. ( 29446107 )	Ciccocioppo R...Corazza GR	2018
3	Coexpression of CD3 and CD20 in Canine Enteropathy-Associated T-cell Lymphoma. ( 29343197 )	Noland EL...Kiupel M	2018
4	Type II enteropathy-associated t-cell lymphoma: A case report and literature review. ( 29888733 )	Zhao L...Zhang Y	2018
5	Pathogenesis of Enteropathy-Associated T Cell Lymphoma. ( 29943210 )	Chander U...Bhagat G	2018
6	An unexpected deterrent in diagnosing refractory celiac disease and enteropathy-associated T-cell lymphoma: a gluten-free diet. ( 30181834 )	Hussain N...Lynch T	2018
7	Perforation of the small intestine caused by enteropathy-associated T cell lymphoma. ( 30302434 )	Kabul S...?zt?rk E	2018
8	Potentially important miRNAs in enteropathy-associated T-cell lymphoma pathogenesis: A pilot study. ( 30989051 )	Clarke L...Flavin R	2018
9	A Case of Type II Enteropathy-Associated T-Cell Lymphoma in a Patient With Ulcerative Colitis. ( 28572650 )	Komeda Y...Kudo M	2017
10	High myeloid-derived suppressor cell frequencies in the duodenum are associated with enteropathy associated T-cell lymphoma and its precursor lesions. ( 27341082 )	Bontkes HJ...de Gruijl TD	2017
11	Enteropathy-associated T-cell lymphoma presenting as cutaneous deposits. ( 27766624 )	Webster A...Miall F	2017
12	Establishment of a Patient-Derived Xenograft of Canine Enteropathy-Associated T-Cell Lymphoma, Large Cell Type. ( 28011041 )	Im KS...Modiano JF	2017
13	Type II Enteropathy-Associated T-cell Lymphoma: A Rare Report from Iran. ( 28316767 )	Nozari N	2017
14	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. ( 28424246 )	Moffitt AB...Dave SS	2017
15	Enteropathy-associated T-cell lymphoma in the US: higher incidence and poorer survival among Asians. ( 26104061 )	Karanam PK...Go RS	2016
16	Cross Lineage Rearrangement in Feline Enteropathy-Associated T-cell Lymphoma. ( 26215761 )	Andrews C...Kiupel M	2016
17	Endoscopic Findings of Enteropathy-Associated T-Cell Lymphoma Type II: A Case Series. ( 26260757 )	Hong YS...Kim JJ	2016
18	Type I enteropathy-associated T-cell lymphoma in the colon of a 29-year-old patient and a brief literature review. ( 26955284 )	Zhang JC...Zhang FX	2016
19	Eosinophil-Rich Acute Febrile Neutrophilic Dermatosis in a Patient With Enteropathy-Associated T-cell Lymphoma, Type 1. ( 27097333 )	Soon CW...Kim J	2016
20	Enteropathy-associated T-cell lymphoma: An extremely rare cause of chronic diarrhoea. ( 27326953 )	Liong CC...Chan WK	2016
21	Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. ( 27600764 )	Roberti A...de Leval L	2016
22	Enteropathy-Associated T-Cell Lymphoma. ( 27900603 )	Ondrejka S...Jagadeesh D	2016
23	A rare but potentially fatal cause of diarrhoea and weight loss: enteropathy-associated T-cell lymphoma. ( 25568262 )	Wali GN...Eagleton HJ	2015
24	Enteropathy-associated T-cell lymphoma in childhood: a case report and review of the literature. ( 25629982 )	Chisini M...Testi AM	2015
25	Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort. ( 25716069 )	Nijeboer P...Bouma G	2015
26	A New and Validated Clinical Prognostic Model (EPI) for Enteropathy-Associated T-cell Lymphoma. ( 25779949 )	de Baaij LR...Cillessen SA	2015
27	Enteropathy-associated T-cell lymphoma: improving treatment strategies. ( 25925928 )	Nijeboer P...Visser O	2015
28	Primary Enteropathy-Associated T-Cell Lymphoma Type 2: An Emerging Entity? ( 26068772 )	Grigg-Gutierrez NM...Toro DH	2015
29	Enteropathy-associated T-cell lymphoma: involvement of the gastrointestinal tract from the duodenum to the rectum. ( 26115398 )	Demir Y...Bayram ?	2015
30	Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. ( 26226842 )	Tomita S...Nakamura N	2015
31	Discordant and metachronous Non-Hodgkin's lymphomas: Enteropathy-associated T-cell lymphoma, Type II with aberrant expression of CD4 presenting several years after a mucosa-associated lymphoid tissue type B-cell lymphoma. ( 26549098 )	Fonseca F...Kulkarni B	2015
32	Successful diagnosis of type II enteropathy-associated T-cell lymphoma using flow cytometry and the cell block technique of celomic fluid manifesting as massive pyoid ascites that could not be diagnosed via emergency laparotomy. ( 24429453 )	Tanaka H...Nakaseko C	2014
33	Detailed clinicopathological characteristics and possible lymphomagenesis of type II intestinal enteropathy-associated T-cell lymphoma in Japan. ( 24746558 )	Kikuma K...Takeshita M	2014
34	Enteropathy-associated T-cell lymphoma, type II (monomorphic variant). ( 24822244 )	Raza A...Zu Y	2014
35	Enteropathy associated T-cell lymphoma presenting with multiple episodes of small bowel haemorrhage and perforation. ( 24876396 )	Pun AH...Loganathan A	2014
36	Enteropathy associated T cell lymphoma-monomorphic variant, presenting as bilateral ovarian masses. ( 24943780 )	Jacob PM...Suchetha S	2014
37	Enteropathy-associated T-cell lymphoma presenting with gastrointestinal tract symptoms: A report of two cases and review of diagnostic challenges and clinicopathological correlation. ( 24959225 )	Jiao G...Wang B	2014
38	Profile of CD103 expression in T-cell neoplasms: immunoreactivity is not restricted to enteropathy-associated T-cell lymphoma. ( 25025448 )	Morgan EA...Pinkus GS	2014
39	An unusual case of enteropathy-associated T-cell lymphoma with CD20 positivity. ( 25308040 )	Misra DS...Malhotra V	2014
40	Enteropathy associated T cell lymphoma - a case report of an uncommon extranodal T cell lymphoma. ( 25478355 )	V G...Amprayil AJ	2014
41	Enteropathy-associated T cell lymphoma as a complication of silent celiac disease. ( 25568762 )	Brito MD...Mariz J	2014
42	A Case of Type II Enteropathy-Associated T-Cell Lymphoma with Epstein-Barr Virus Positivity. ( 25588633 )	Song MJ...Huh J	2014
43	Hemophagocytic Lymphohistiocytic Syndrome and Enteropathy-Associated T-cell Lymphoma in a Patient with Refractory Celiac Disease. ( 26157854 )	Lu L...Puglia M	2014
44	Celiac disease, enteropathy-associated T-cell lymphoma, and primary sclerosing cholangitis in one patient: a very rare association and review of the literature. ( 24381773 )	Majid N...Errihani H	2013
45	Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. ( 23313469 )	Malamut G...Cellier C	2013
46	Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. ( 23361910 )	Jantunen E...Lymphoma Working Party of the EBMT	2013
47	Brentuximab in the treatment of CD30-positive enteropathy-associated T-cell lymphoma. ( 23411380 )	Khalaf WF...Reddy N	2013
48	Clinically undiagnosed enteropathy associated T-cell lymphoma type II presenting with prolonged lower gastrointestinal tract symptoms: report of an autopsy case and review of diagnostic challenges and clinicopathological correlation. ( 23450273 )	Rand AJ...Lagoo AS	2013
49	Hemophagocytic lymphohistiocytosis: an uncommon presentation of enteropathy-associated T-cell lymphoma. ( 23530098 )	Varghese D...Benjamin S	2013
50	Enteropathy-associated T-cell lymphoma diagnosed and followed-up by using double-balloon enteroscopy. ( 23541443 )	Fukushima M...Inokuma T	2013

Sources

Genes for Enteropathy-Associated T-Cell Lymphoma

Genes related to Enteropathy-Associated T-Cell Lymphoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	SETD2	SET Domain Containing 2, Histone Lysine Methyltransferase	Protein Coding	17.53	GeneCards inferred via : Publications (show sections)
2	CCL11	C-C Motif Chemokine Ligand 11	Protein Coding	17.18	GeneCards inferred via : Publications (show sections)
3	CD3G	CD3g Molecule	Protein Coding	17.18	GeneCards inferred via : Publications (show sections)
4	ITGAE	Integrin Subunit Alpha E	Protein Coding	17.18	GeneCards inferred via : Publications (show sections)

Sources

Variations for Enteropathy-Associated T-Cell Lymphoma

Sources

Expression for Enteropathy-Associated T-Cell Lymphoma

Search GEO for disease gene expression data for Enteropathy-Associated T-Cell Lymphoma.

Sources

Pathways for Enteropathy-Associated T-Cell Lymphoma

Pathways related to Enteropathy-Associated T-Cell Lymphoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Akt Signaling ⁶⁵ Show member pathways p38 Signaling ⁶⁵ Tec Kinases Signaling ⁶⁵	12.48	CCL11 CD3G ITGAE
2	G-protein signaling_Regulation of RAC1 activity ²³	10.64	CD3G ITGAE
3	Reelin Pathway (Cajal-Retzius cells) ⁶⁵	10.63	CD3G ITGAE

Sources

GO Terms for Enteropathy-Associated T-Cell Lymphoma

Cellular components related to Enteropathy-Associated T-Cell Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	external side of plasma membrane	GO:0009897	8.62	CD3G ITGAE

Sources

Sources for Enteropathy-Associated T-Cell Lymphoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia